Synergistic therapeutic strategy of dual drug-loaded lipid polymer hybrid nanoparticles for breast cancer treatment

7Citations
Citations of this article
26Readers
Mendeley users who have this article in their library.

Abstract

In this investigation, a smart nanocarrier-loaded docetaxel, a microtubules disrupting agent and vorinostat, a histone deacetylase inhibitor was developed to achieve a synergistic anticancer effect. Dual drug-loaded lipid polymer hybrid nanoparticles were prepared, with easy fabrication and favourable properties including small size, narrow distribution and a high loading efficacy. The in vitro drug release conducted in phosphate-buffered saline, pH 7.4 and acetate-buffered saline, pH 5.5 media demonstrated the sustained, pH-dependent release profile. The nanoparticles were effectively taken up by cells, which ensured greater suppression of cell growth. The co-delivery of both drugs exhibited a synergistic effect on the induction of cancer cell apoptosis, resulting in greater inhibition of SCC-7, MCF-7, and MDA-MB-231 cancer cells by the drug-loaded carrier. These promising results may lead to clinical applications with enhanced docetaxel activity.

Cite

CITATION STYLE

APA

Tran, T. H., Nguyen, H. T., Yong, C. S., Truong, D. H., & Kim, J. O. (2019). Synergistic therapeutic strategy of dual drug-loaded lipid polymer hybrid nanoparticles for breast cancer treatment. Indian Journal of Pharmaceutical Sciences, 81(3), 474–482. https://doi.org/10.36468/pharmaceutical-sciences.532

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free